AbbVie Earnings Preview: Will Humira's Expiry, New CEO Fuel A Bullish Surge?
AbbVie Earnings Preview: Will Humira's Expiry, New CEO Fuel A Bullish Surge?
AbbVie Inc (NYSE:ABBV) will report second-quarter earnings on Thursday and Wall Street expects $2.96 in earnings per share and $14 billion in revenues as the company reports before market hours.
AbbVie公司（纽交所：ABBV）将于周四发布第二季度收益报告。华尔街预计该公司在市场开盘前公布每股收益为2.96美元，营收为140亿美元。
AbbVie investors and analysts will be focusing on the revenue impact of arthritis drug Humira following its U.S. patent expiry, after a significant first-quarter decline.
在衡量制痛药Humira的营业收入影响时，AbbVie的投资者和分析师将关注它在美国专利到期后的情况，鉴于第一季度出现了显著下降。
Also, with new CEO Robert A. Michael at the helm and strong growth from Humira's replacements, investors will be looking for signs of recovery and market optimism.
此外，在新任CEO Robert A. Michael的领导下，加之Humira的替代品表现良好，投资者将寻找复苏和市场乐观的迹象。
The stock is up 20.93% over the past year, 11.73% year-to-date.
过去一年，该股上涨了20.93%，同期增幅为11.73%。
Let's look at what the charts indicate for AbbVie stock, and how the stock currently maps against Wall Street estimates.
让我们来看一下AbbVie股票的图表指标，以及该股票目前如何与华尔街的预测相匹配。
AbbVie Stock Trend Bullish Ahead Of Q2 Earnings
AbbVie股票趋势看好：二季度收益在前。
AbbVie's stock shows a strongly bullish trend, with the share price of $173.15 surpassing its 5, 20, and 50-day exponential moving averages. This technical setup indicates a robust upward momentum.
AbbVie的股票呈现出非常看好的趋势，股价达到173.15美元，超过了其5天，20天和50天的指数移动平均线。这种技术设置表明它正呈现出强劲的上升动力。
Chart created using Benzinga Pro
使用Benzinga Pro创建的图表
Specifically, the stock is trading above its 8-day ($171.43), 20-day ($169.69), 50-day ($166.47), and 200-day ($161.99) simple moving averages, signaling bullish conditions.
具体而言，该股票正在交易于其8天（$171.43），20天（$169.69），50天（$166.47）和200天（$161.99）的简单移动平均线之上，表明看好的状态。
Chart created using Benzinga Pro
使用Benzinga Pro创建的图表
The Moving Average Convergence Divergence (MACD) indicator, at 1.53, reinforces this bullish stance.
移动平均收敛发散（MACD）指标位于1.53，强化了这种看好的立场。
However, with an RSI of 57.65, and treading higher — the stock might be approaching overbought territory, suggesting caution.
然而，随着RSI指标达到57.65，且还在上升中，这种股票可能正在接近超买区域，建议谨慎。
The Bollinger Bands further support a bullish outlook, with the 25-day bands at $164.88 to $175.13 and the stock trading in the upper band.
布林带进一步支持看好的前景，25天带位于164.88至175.13美元，该股票交易于上轨区间。
Despite the current selling pressure, which could imply potential for bearish movement, the overall technical indicators favor a bullish position for AbbVie stock.
尽管当前存在卖压，这可能意味着潜在的看淡动作，但总体技术指标都看好AbbVie的头寸。
Read Also: AbbVie Appeals To Supreme Court Over Attorney-Client Privilege In 'Long-Standing' AndroGel Case
阅读更多内容：AbbVie就“长期”AndroGel案件中的律师-客户特权向最高法院上诉。
AbbVie Analysts Consensus Ratings
AbbVie分析师的共识评级。
Ratings & Consensus Estimates: The consensus analyst rating on AbbVie stock stands at an Overweight currently with a price target of $173. Recent analyst ratings from BMO Capital, Morgan Stanley, and Cantor Fitzgerald, in July, have an average price target of $203.33 for AbbVie stock, implying a potential 17.67% upside.
评级和共识预估：目前AbbVie股票的共识分析师评级为“超配”，目标价为173美元。BMO Capital、大摩资源lof和Cantor Fitzgerald在7月的分析师评级中，对AbbVie股票的平均目标价为203.33美元，意味着潜在的17.67%增长。
ABBV Price Action: AbbVie stock was trading at $172.80 at the time of publication.
发布时，AbbVie股票的交易价格为172.80美元。
- Is Big Pharma Poised To Take Over Cannabis? 3 Companies Already Manage 8 In 10 Drug Prescriptions In The US
- 大药企是否有望接管大麻股？美国已有3家公司掌控了10份处方药中的8份